Max Lafontan

16.7k total citations · 4 hit papers
235 papers, 13.5k citations indexed

About

Max Lafontan is a scholar working on Physiology, Molecular Biology and Animal Science and Zoology. According to data from OpenAlex, Max Lafontan has authored 235 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Physiology, 75 papers in Molecular Biology and 53 papers in Animal Science and Zoology. Recurrent topics in Max Lafontan's work include Adipose Tissue and Metabolism (144 papers), Receptor Mechanisms and Signaling (57 papers) and Pharmacological Effects and Assays (49 papers). Max Lafontan is often cited by papers focused on Adipose Tissue and Metabolism (144 papers), Receptor Mechanisms and Signaling (57 papers) and Pharmacological Effects and Assays (49 papers). Max Lafontan collaborates with scholars based in France, Czechia and United States. Max Lafontan's co-authors include M Berlan, Jean Galitzky, Dominique Langin, Anne Bouloumié, Coralie Sengenès, Rudi Busse, Cédric Moro, Christian Carpéné, F. Crampes and Isabelle de Glisezinski and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

Max Lafontan

234 papers receiving 13.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipolysis and lipid mobilization in human adipose tissue

2009 584 citations Max Lafontan, Dominique Langin profile →
Leptin induces oxidative stress in human endothelial cells

1999 567 citations Anne Bouloumié, Max Lafontan et al. profile →
Leptin, the Product of Ob Gene, Promotes Angiogenesis

1998 561 citations Max Lafontan et al. profile →
Fat cell adrenergic receptors and the control of white and brown fat cell function

1993 519 citations Max Lafontan, M Berlan profile →

Peers

Countries citing papers authored by Max Lafontan

Since Specialization

Citations

This map shows the geographic impact of Max Lafontan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Lafontan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Lafontan more than expected).

Fields of papers citing papers by Max Lafontan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Lafontan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Lafontan. The network helps show where Max Lafontan may publish in the future.

Co-authorship network of co-authors of Max Lafontan

This figure shows the co-authorship network connecting the top 25 collaborators of Max Lafontan. A scholar is included among the top collaborators of Max Lafontan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Lafontan. Max Lafontan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sugar-Sweetened Beverages and Weight Gain in Children and Adults: A Systematic Review from 2013 to 2015 and a Comparison with Previous Studies 2017 ·Obesity Facts ·Maria Luger, Max Lafontan, Maira Bes‐Rastrollo, Eva Winzer, Volkan Yumuk, Nathalie J. Farpour‐Lambert	225
2	Adipose tissue and adipocyte dysregulation 2013 ·Diabetes & Metabolism ·Max Lafontan	153
3	Recommendations for healthier hydration: addressing the public health issues of obesity and type 2 diabetes 2012 ·Clinical Obesity ·Lawrence E. Armstrong, Sı́món Barquera, (unknown), (unknown), David Haslam, Max Lafontan	11
4	Role of Sugar Intake in Beverages on Overweight and Health 2010 ·Nutrition Today ·Max Lafontan	1
5	Control of lipolysis by natriuretic peptides and cyclic GMP 2008 ·Trends in Endocrinology and Metabolism ·Max Lafontan, Cédric Moro, M Berlan, F. Crampes, Coralie Sengenès, Jean Galitzky	179
6	Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes 2003 ·International Journal of Obesity ·Karine Lolmède, (unknown), Jean Galitzky, Max Lafontan, Anne Bouloumié	167
7	[Lipid metabolism in adipose tissue: adrenergic control of the adipocyte and mobilization if the lipids]. 2001 ·PubMed ·Max Lafontan	1
8	Expression of Human α2-Adrenergic Receptors in Adipose Tissue of β3-Adrenergic Receptor-deficient Mice Promotes Diet-induced Obesity 2000 ·Journal of Biological Chemistry ·Philippe Valet, Danica Grujić, Jennifer M. Wade, Moriko Ito, (unknown), (unknown), Susan R. Ross, Reed A. Graves, Saverio Cinti, Max Lafontan, Bradford B. Lowell	80
9	Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism 1996 ·Proceedings of The Nutrition Society ·Dominique Langin, Cecilia Holm, Max Lafontan	139
10	Regulation of beta₃‐adrenoceptor expression in white fat cells* 1995 ·Fundamental and Clinical Pharmacology ·Dominique Langin, Geneviève Tavernier, Max Lafontan	37
11	Differential activation of β₁‐, β₂‐ and β₃‐adrenoceptors by catecholamines in white and brown adipocytes 1995 ·Fundamental and Clinical Pharmacology ·(unknown), Christian Carpéné, Alain Bousquet‐mélou, M Berlan, Max Lafontan	31
12	[Adrenergic regulation of lipolysis and vascularization of the adipose tissue]. 1994 ·PubMed ·Max Lafontan	0
13	Imidazoline Binding Sites in Fat Cells 1992 ·American Journal of Hypertension ·Max Lafontan, Dominique Langin, María P. Portillo, Hervé Paris	8
14	Thermogenic and lipolytic effect of yohimbine in the dog 1991 ·British Journal of Pharmacology ·Jean Galitzky, M. Vermorel, Max Lafontan, P Montastruc, M Berlan	20
15	Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. 1990 ·Journal of Clinical Investigation ·Philippe Valet, M Berlan, M Beauville, F. Crampes, J L Montastruc, Max Lafontan	71
16	Discrimination between α2-adrenoceptors and [3H]idazoxan-labelled non-adrenergic sites in rabbit white fat cells 1990 ·European Journal of Pharmacology Molecular Pharmacology ·Dominique Langin, Hervé Paris, Michèle Dauzats, Max Lafontan	28
17	Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists. 1989 ·Journal of Pharmacology and Experimental Therapeutics ·Jean Galitzky, Pascale Mauriège, M Berlan, Max Lafontan	21
18	Mechanism of lipolytic action of a new alpha-2 adrenergic antagonist of the piperazinopyrimidine family: RP 55462. 1989 ·Journal of Pharmacology and Experimental Therapeutics ·Jean Sébastien Saulnier‐Blache, Mohammed Taouis, Michèle Dauzats, A. Uzan, M Berlan, Max Lafontan	3
19	Study of platelet alpha 2-adrenoceptors in Parkinson's disease. 1987 ·PubMed ·Montastruc Jl, (unknown), M Berlan, Max Lafontan, C. Caranobe, B Boneu, A Rascol	1
20	La lipolyse adrénergique du tissu adipeux humain: propriétés et rôle physiologique des alpha récepteurs. 1980 ·M Berlan, Max Lafontan, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact